Association between angiogenesis soluble factors and disease progression markers in chronic hepatitis C patients
X Salcedo Mora1, P Sanz-Cameno, J Medina
1Unit of Hepatology, Hospital Universitario de La Princesa, Universidad Autónoma, Madrid, Spain.
Insights
Chronic hepatitis C patients have elevated angiogenesis soluble factors (ASFs). These factors correlate with liver inflammation, fibrosis, and transaminase levels, indicating their role in disease progression.
Area of Science:
- Hepatology
- Angiogenesis Research
- Biochemistry
Background:
- Chronic hepatitis C (CHC) is a significant global health concern.
- Angiogenesis plays a role in liver disease progression.
- Understanding angiogenesis soluble factors (ASFs) in CHC is crucial for disease management.
Purpose of the Study:
- To compare ASF levels in CHC patients versus healthy controls.
- To investigate the association between ASF levels and disease markers in CHC.
Main Methods:
- Serum samples from 36 CHC patients and 15 healthy controls were analyzed.
- Levels of VEGF, sFlt-1, sFlk-1, PlGF, Ang-2, and sTie-2 were quantified using ELISA.
- CHC patients underwent liver biopsy for histological assessment.
Main Results:
- CHC patients exhibited significantly higher serum levels of PlGF, Ang-2, and sFlt-1 compared to controls.
- Serum VEGF and Tie-2 levels correlated with inflammation grade.
- PlGF levels correlated with fibrosis stage, and Flt-1/Flk-1 correlated with transaminase levels.
Conclusions:
- CHC patients demonstrate elevated serum ASF levels.
- Specific ASFs are significantly correlated with key indicators of CHC disease severity, including inflammation, fibrosis, and biochemical markers.
Objectives:
Our objectives were to compare angiogenesis soluble factor (ASF) levels in chronic hepatitis C (CHC) patients and healthy individuals, and to investigate potential associations between ASF levels and both histological and biochemical markers of disease progression.
Method:
Thirty-six patients (69% males) positive for HCV-RNA by PCR analysis were included in the study. All patients underwent liver biopsy before treatment. Serum levels of vascular endothelial growth factor (VEGF), soluble Flt-1 and Flk-1 receptors, placental growth factor (PlGF), angiopoietin-2 (Ang-2) and soluble Tie-2 receptor were determined by ELISA. Fifteen healthy subjects were used as controls.
Results:
In comparison to healthy individuals, CHC patients showed significantly increased serum levels of proangiogenic factors PlGF (22 +/- 5 vs. 18 +/- 8 pg/ml; p < 0.05), Ang-2 (1265 +/- 385 vs. 833 +/- 346 pg/ml; p < 0.005) and sFlt-1 (95 +/- 22 vs. 72 +/- 14 pg/ml; p < 0.0001). Interestingly, in CHC patients serum levels of VEGF and Tie-2 correlated with grade of inflammation, PlGF correlated with stage of fibrosis, and Flt-1 and Flk-1 correlated with serum transaminase levels (p < 0.05 in all cases).
Conclusions:
CHC patients showed increased serum levels of ASF, and a significant correlation was shown between serum levels of selected ASFs and grade of inflammation, stage of fibrosis, and transaminase levels.
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
01:24Cirrhosis II: Pathophysiology